Systems and methods for treating sexual disorders using electro-stimulation

ABSTRACT

Systems and methods are provided for treating a sexual disorder such as erectile dysfunction (ED) or female sexual arousal disorder (FSAD). An electrical stimulation system may include an implantable stimulation unit, an external patient controller, and an external physician controller. The implantable stimulation unit has an array of electrodes disposed on one or more flexible substrates configured to conform to a patient&#39;s anatomy at the pelvic plexus. Post-implantation, the physician controller may direct the stimulation unit to stimulate with select electrode(s) of the array to determine which electrode configuration provides optimal sexual arousal. The patient controller may be used to cause the stimulation unit to stimulate using the optimal electrode configuration at desired times.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.14/880,903, filed Oct. 12, 2015, which claims the benefit of priority ofU.S. Provisional Patent Application No. 62/063,301, filed Oct. 13, 2014,the entire contents of each of which are incorporated herein byreference.

FIELD OF THE INVENTION

The present disclosure relates to implantable electrical stimulationsystems and methods for treating and preventing sexual disorders such aserectile dysfunction, female sexual arousal disorders, erectiledysfunction following prostatectomy surgery, and erectile dysfunctionassociated with spinal cord injury.

BACKGROUND OF THE INVENTION

A sexual disorder (e.g., sexual dysfunction, sexual malfunction) is acomplication experienced by an individual, male or female, or a coupleduring any stage of normal sexual activity, including erection, physicalpleasure, desire, preference, arousal, or orgasm. Sexual dysfunctionsgenerally have a profound impact on an individual's quality of life. Themost prevalent sexual disorders are erectile dysfunction (ED) and femalesexual arousal disorders (FSAD).

Penile erection is a coordinated neurocardiovascular response. See, DeanR C and Lue T F, Physiology of penile erection and pathophysiology oferectile dysfunction, Urol Clin North Am. 2005 November; 32(4):379-95.In the flaccid state, the penile smooth muscles are tonicallycontracted, allowing only a small amount of blood flow for nutritionalpurposes. Penile erection occurs when sexual stimulation triggersrelease of neurotransmitters, mainly nitric oxide, from the cavernousnerve terminals. The neurotransmitters cause relaxation of the smoothmuscle cells in cavernosal arterioles and sinuses, resulting inincreased blood flow into the penis. This causes the cavernous sinusesto fill with blood and expand against the tunica albuginea, partiallyoccluding the venous outflow, thus resulting in an erection.

ED is a multi-causal disease with diversified etiologies, and may bepsychogenic, vasculogenic, hormonal, or neurogenic. However, studiesshow that the neurogenic and vasculogenic causes are the most prevalent.In general, the major mechanisms responsible for ED are a failure in theneuronal response (e.g., prostatectomy, cystectomy, abdominoperinealresection, spinal cord injury, or diabetes) or an increase in the toneand/or contractility of the smooth muscle within the corpus cavernosumand penile arteries (e.g., hypertension, atherosclerosis and diabetes).See, Sadeghi-Nej ad H., Penile prosthesis surgery: a review ofprosthetic devices and associated complications, Sex Med. 2007 March;4(2):296-309.

Prostatectomy is known to cause severe ED. This essential surgicalprocedure, generally for treatment of prostate cancer, often leads to EDdue to the inevitable disruption of the neural pathway for erectilefunction. These intimal nerves are located around the prostate, and maybe damaged during the surgery. Currently, surgeons attempt to perform anerve-sparing surgery; however, in the actual scenario, an astounding70% of patients undergoing prostatectomy will develop ED. See, Penson DF, McLerran D, Feng Z, Li L, Albertsen P C, Gilliland F D, Hamilton A,Hoffman R M, Stephenson R A, Potosky A L, Stanford J L., 5-year urinaryand sexual outcomes after radical prostatectomy: results from theProstate Cancer Outcomes Study, J Urol. 2008 May; 179(5 Suppl): S40-4.

Pharmacological treatments are currently available for ED. These drugs(e.g., sildenafil, Viagra®; tadalafil, Cialis® or vardenafil, Levitra®)are efficient for the majority of ED patients; however, they show loweffectiveness for ED resulting from prostatectomy or others causesassociated with failure in the neuronal response. Such drugs act bypotentiating the actions of the neurotransmitter nitric oxide, byinhibiting the enzyme phosphodiesterase type 5 [PDE-5). See, Rotella DP., Phosphodiesterase 5 inhibitors: current status and potentialapplications, Nat Rev Drug Discov. 2002 September; 1(9):674-82. PDE-5 isan enzyme responsible for breaking down the intracellular secondmessenger cGMP generated by NO stimulus. cGMP is involved in theregulation of some protein-dependent kinases, which relax smooth musclecells and facilitate erection. Thus, patients with disruption of theerectile neural response do not respond well to such medications. Onealternative for these patients is intrapenial injections ofvasodilators, which produce direct erection, independent of the neuralpathway. See, Leungwattanakij S, Flynn V Jr, Hellstrom W J,Intracavernosal injection and intraurethral therapy for erectiledysfunction, Urol Clin North Am. 2001 May; 28(2):343-54 and Harding L M,Adeniyi A, Everson R, Barker S, Ralph D J, Baranowski A P, Comparison ofa needle free high-pressure injection system with needle-tippedinjection of intracavernosal alprostadil for erectile dysfunction, Int JImpot Res. 2002 December; 14(6):498-501. Alprostadil (Prostaglandin E1,PGE1) is the most common vasodilator used for ED. See, Harding andEardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K,McVary K, Munarriz R, Lee S W, Pharmacotherapy for erectile dysfunction,J Sex Med. 2010 January; 7(1 Pt 2):524-40. The vasodilator may beinjected into the corpus cavernosum with a needle and is effective inover 80% of patients. See, Harding. Common side effects of intrapenialinjection are penile pain, bleeding, hematoma, priapism, and penilefibrosis, which can lead to permanent ED. See, Leungwattanakij.

Another option for these patients is penile implants, which consist of apair of malleable or inflatable rods surgically implanted within theerection chambers of the penis. See, Sadeghi-Nejad. There are differenttypes of penile prosthesis (rigid, semi-rigid, or inflatable) and allthem normally require an irreversible and destructive surgery with riskof intra and post-operative complications. Such prosthesis frequentlyrequire surgery revision. Nevertheless, prosthesis implantation is acommon procedure due to the lack of better treatment options. Thus,there is a clear need for better therapeutic strategy for the treatmentof ED resulting from failure of the neural pathway, such aspost-prostatectomy ED, providing a painless, safe, easier, non-traumaticand more effective alternative.

Numerous studies have shown that cavernous nerve stimulation can induceand maintain erection in animals and men. See, Lue T F, Schmidt R A,Tanagho E A, Electrostimulation and penile erection, Urol Int. 1985;40(1):60-4; Shafik A, Shafik A A, Shafik I A, El Sibai O., Percutaneousperineal electrostimulation induces erection: clinical significance inpatients with spinal cord injury and erectile dysfunction, J Spinal CordMed. 2008; 31(1):40-3; and Shafik A, el-Sibai O, Shafik A A, Magneticstimulation of the cavernous nerve for the treatment of erectiledysfunction in humans, Int J Impot Res. 2000 June; 12(3):137-41. Sincethen, electroneurostimulation for erectile response has been consideredan option for patients undergoing prostatectomy. However, no one hasdeveloped an implantable neuroelectrostimulation system specifically forED that reached satisfactory results in the clinic. The barrier for thedevelopment of such technology is the complex anatomy of the humancavernous nerve. See, Klotz L., Intraoperative cavernous nervestimulation during nerve sparing radical prostatectomy: how and when?Curr Opin Urol. 2000 May; 10(3):239-43 and Ponnusamy K, Sorger J M, MohrC., Nerve mapping for prostatectomies: novel technologies underdevelopment, J Endourol. 2012 July; 26(7):769-77. Locating the optimalsite for electroneurostimulation is difficult, since the human cavernousnerve travels from the pelvic-plexus to the penis through a complexanastomosis. Moreover, there is a significant anatomic variability inthe location of the cavernous nerve. Each patient's anatomy, diseasestage, and cancer location are unique. The pelvic-plexus is a diaphanousveil with microscopic nerves and the cavernous nerve is not disposeduniformly in every man. Therefore, these barriers make theidentification of the cavernosal nerve segments for selectivestimulation extremely difficult.

In previously proposed systems, localization and identification of thecavernosal nerve is conducted during implantation surgery. For example,U.S. Pat. No. 4,585,005 to Lue requires previous identification andisolation of the cavernous nerves. U.S. Pat. No. 7,328,068 to Spinellidescribes a method for stimulation of the penile neural pathway in whichprecise positioning of the implant is required to provide optimalstimulation. In Spinelli, a neurophysiological monitoring assessmentcould be used as method to locate the optimal stimulation site beforeimplantation. U.S. Pat. No. 7,330,762 to Boveja discloses systems forelectroneurostimulation of the cavernosal nerve, including differenttypes of electrodes, such as spiral electrodes, cuff electrodes, steroideluting electrodes, wrap-around electrodes and hydrogel electrodes.Again, identification of the optimal site for stimulation is requiredbefore implantation. U.S. Pat. No. 7,865,243 to Whitehurst describessystems and methods for stimulation of the cavernosal nerve; however,the anatomical identification of the course of the pudendal nerve and/orother nerves to be stimulated must be located before implantation.

Overall, these prior art systems and methods require identification ofthe optimal site of stimulation prior to implantation and tend to demandextensive operatory period, increasing the intra and post-operativerisks and complications.

SUMMARY OF THE INVENTION

The present disclosure provides a neuroelectrostimulation system andmethods for treating a sexual disorder, including in patients who areincapable of obtaining penile erections spontaneously (e.g., erectiledysfunction (ED) including ED associated with failure in the neuronalresponse such as post-prostatectomy ED) and patients suffering fromfemale sexual arousal disorder (FSAD).

An electrical stimulation system for treatment of a sexual disorder,e.g., ED, in a patient may include an implantable stimulation unit, anexternal patient controller, and an external physician controller.

The implantable stimulation unit may include an array of electrodesdisposed on at least one flexible substrate sized and shaped to abut atleast a portion of a pelvic plexus of a patient and a programmablecontroller operatively coupled to the array of electrodes. Theprogrammable controller may include a stimulation circuit, a nonvolatilememory, and a microprocessor coupled to the stimulation circuit and thenonvolatile memory. The nonvolatile memory may store an identity of anempirically determined subset of the array of electrodes and astimulation routine used by the microprocessor to supply electricalstimulation via the stimulation circuit and the pelvic plexus to anerve(s), e.g., at least one cavernous nerve, sufficient to cause sexualarousal, e.g., an erection. The stimulation routine may include a pulseduration, frequency, voltage, and current. Such parameters of electricalstimulation may be adjusted post-implantation by the external physiciancontroller and, optionally, by the external patient controller. Theimplantable stimulation unit may have a power supply that may berechargeable.

The external patient controller may be configured to selectably activatethe implantable stimulation unit responsive to a patient input. Theexternal physician controller may be configured to selectively activatedesired subsets of the array of electrodes to determine the empiricallydetermined subset of the array of electrodes and to cause thenonvolatile memory of the implantable stimulation unit to store thestimulation routine used by the microprocessor. The subset of the arrayof electrodes may include one or more electrodes within the array ofelectrodes.

The external physician controller may be configured to selectivelyactivate desired subsets of the array of electrodes by causing themicroprocessor to execute a scanning protocol stored in the nonvolatilememory to determine the empirically determined subset of the array ofelectrodes. The scanning protocol may be configured to cause themicroprocessor to supply electrical stimulation via the stimulationcircuit by activating varying subsets of the array of electrodes in apredetermined manner to determine the empirically determined subset ofthe array of electrodes and to cause the nonvolatile memory of theimplantable stimulation unit to store the stimulation routine used bythe microprocessor. Activating varying subsets of the array ofelectrodes in a predetermined manner may include activating a firstsubset of the array of electrodes at a first time and activating asecond subset of the array of electrodes at a second time in aninterpulse manner.

The implantable stimulation unit and the external patient controllercommunicate wirelessly. In that regard, the implantable stimulation unitmay contain a first transceiver and the external patient controller maycontain a second transceiver. The first and second transceivers mayemploy IEEE 802.11 or BLUETOOTH™ communications schemes. Wirelesscommunications between the first and second transceivers may beencrypted. The external patient controller may be specifically designedfor communication with the implantable stimulation unit or may be asmartphone, laptop, tablet, or smartwatch programmed to communicate withthe implantable stimulation unit.

The implantable stimulation unit and the external physician controllercommunicate wirelessly and the external physician controller may containa third transceiver. The first and third transceivers may employ IEEE802.11 or BLUETOOTH™ communications schemes. Wireless communicationsbetween the first and third transceivers may be encrypted. The externalphysician controller may be specifically designed for communication withthe implantable stimulation unit or may be a smartphone, laptop, tablet,or desktop computer programmed to communicate with the implantablestimulation unit.

The external physician controller may be configured to selectivelyactivate desired subsets of the array of electrodes to determine theempirically determined subset of the array of electrodes at the time ofimplantation of the implantable stimulation unit and/or subsequent toimplantation of the implantable stimulation unit.

The at least one flexible substrate may be configured to conform to ananatomical shape of the patients nerves such as a portion of the pelvicplexus. In one embodiment, the at least one flexible substrate comprisesa first flexible substrate configured to conform to a first half of thepelvic plexus and a second flexible substrate configured to conform to asecond half of the pelvic plexus. A first portion of the array ofelectrodes may be disposed on the first flexible substrate and a secondportion of the array of electrodes may be disposed on the secondflexible substrate, such that the stimulation circuit may be configuredto cause one or more electrodes of the first portion and one or moreelectrodes of the second portion to supply electrical stimulation at thesame time in a bilateral stimulation manner. The electrodes of the arrayof electrodes may be arranged in a plurality of rows and a plurality ofcolumns disposed on the at least one flexible substrate, such that eachelectrode is individually selectable.

The implantable stimulation unit may include one or more anchorsconfigured to maintain the at least one flexible substrate in contactwith the pelvic plexus following radical prostatectomy. The anchors maybe, for example, sutures or biocompatible glue.

The at least one flexible substrate may include at least one cavityconfigured to permit connective tissue growth in and/or through theflexible substrate(s) to anchor the flexible substrate(s) adjacent tothe pelvic plexus. In addition to providing sexual arousal, theelectrical stimulation may promote nerve regeneration.

Also provided herein are methods for implanting the implantablestimulation unit, methods for determining the subset of the array ofelectrodes for stimulation to cause optimal sexual arousal, and methodsfor using the system. The implantable stimulation unit may be configuredfor implantation using a robotic-guided surgery system. The at least oneflexible substrate and the programmable controller may each be sized andshaped to be implanted through a trocar. At least one electrode of thearray of electrodes may be configured to receive an electrical signalemitted by one or more external electrodes, e.g., electrodes disposed ona skin of a penis of the patient. The nonvolatile memory of theprogrammable controller may be configured to record and storeinformation indicative of the received electrical signal. Theinformation may be transmitted to external patient controller and/orexternal physician controller. The information may be used to determinethe subset of the array of electrodes for stimulation to cause optimalsexual arousal by a user and/or automatically.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the presentdisclosure will become apparent from the following description, appendedclaims, and the accompanying exemplary embodiments shown in thedrawings, which are briefly described below.

FIG. 1 is a schematic representation of an exemplary electricalstimulation system constructed in accordance with the principles of thepresent disclosure.

FIGS. 2A and 2B show front and perspective views, respectively, ofschematic representations of possible electrode shapes within a flexiblesubstrate.

FIGS. 2C through 2E are schematic representations of an exemplaryimplantable stimulation unit of the stimulation system of FIG. 1,wherein FIGS. 2D and 2E show the conformable nature of the implantablestimulation unit such that electrodes may be aligned adjacent to thepatient's pelvic plexus.

FIG. 3 shows a generalized block diagram of an exemplary programmablecontroller of an implantable stimulation unit of the stimulation systemof FIG. 1.

FIG. 4 shows a generalized block diagram of an exemplary externalpatient controller of the stimulation system of FIG. 1.

FIG. 5 is a block diagram of the functional components of an exemplarysoftware-based programming system configured to run on the externalphysician controller of the stimulation system of FIG. 1.

FIG. 6 is a schematic representation of the local anatomy.

FIG. 7 illustrates positioning of the implantable stimulation unit onthe neuronal pelvic plexus.

FIG. 8 shows an exemplary method for empirically determining a subset ofthe array of electrodes for stimulation to cause optimal sexual arousal.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following description is of the best mode presently contemplated forcarrying out the invention. This description is not to be taken in alimiting sense, but is made merely for the purpose of describing thegeneral principles of the invention. The scope of the invention shouldbe determined with reference to the claims.

Systems and methods described herein may be used to treat a sexualdisorder such as erectile dysfunction (ED), including ED associated withfailure in the neuronal response (resulting from e.g., prostatectomy,cystectomy, abdominoperineal resection, spinal cord injury, and/ordiabetes) and ED associated with an increase in the tone and/orcontractility of the smooth muscle within the corpus cavernosum andpenile arteries (resulting from e.g., hypertension, atherosclerosis,and/or diabetes), and female sexual arousal disorder (FSAD).

Penile erection occurs when sexual stimulation triggers release ofneurotransmitters, mainly nitric oxide, from the cavernous nerveterminals. Erectile dysfunction (ED) is a multicausal disease withdiversified etiologies, and neurogenic ED is one of the most prevalent.Several conditions may impair the neuronal pathway for penile erection(e.g., prostatectomy, cystectomy, abdominoperineal resection, spinalcord injury, or diabetes) which lead to a malfunction or interruption ofthe neurotransmitters release by cavernous nerve terminals in erectiletissues.

Systems and methods described herein are expected to restore function ofa denervated penis by, for example, electrostimulating the terminalextremity of the cavernosal nerve. The neuronal pathway triggering theerectile response is a parasympathetic input originated from the pelvicsplanchnic nerve plexus. The pelvic splanchnic nerve plexus is comprisedof branches from the second, third, and fourth sacral nerves thatintertwine with the inferior hypogastric plexus, forming the network ofnerves in the pelvis. The cavernous nerves are derived from the pelvicsplanchnic nerves, travel along via the prostatic plexus, nearly locatedaround the prostate, and supply parasympathetic fibers to the corporacavernosal and corpus spongiosum of the penis. Therefore, locating theoptimal site for electroneurostimulation is difficult, since the humancavernous nerve travels from the pelvic-plexus to the penis through acomplex anastomosis. Moreover, there is a significant anatomicvariability in the location of the cavernous nerve. Each patient'sanatomy, disease stage, and/or cancer location is unique. Thepelvic-plexus is a diaphanous veil with microscopic nerves and thecavernous nerves do not follow uniform localization in every man.Therefore, these barriers make identification of the cavernosal nervesegments for selective stimulation extremely difficult. Provided hereinare systems and methods for overcoming these barriers.

Referring to FIG. 1, an overview of an exemplary electrical stimulationsystem constructed in accordance with the principles of the presentdisclosure is provided. In FIG. 1, components of the system are notdepicted to scale on either a relative or absolute basis. Electricalstimulation system 100 may include implantable stimulation unit 200having programmable controller 300, external patient controller 400, andexternal physician controller 500.

Implantable stimulation unit 200 includes array 202 of electrodesdisposed on at least one flexible substrate, illustratively firstflexible substrate 204 and second flexible substrate 206, cable 208, andprogrammable controller 300. The electrodes of array 202 are configuredto emit electrical energy to stimulate tissue. Preferably, theelectrodes are individually selectable and one or more pairs ofelectrodes may be selected by a user, e.g., a physician using externalphysician controller 500, for stimulation. The electrodes of array 202may be arranged uniformly and/or disposed in different spatialconfiguration. For example, electrodes of array 202 may be spaced apartby about 0.05 mm to about 5.0 mm, about 0.1 mm to about 4.0 mm, about0.5 mm to about 3.0 mm, or about 0.5 mm to about 1.5 mm. Illustratively,the electrodes are arranged in a plurality of rows and a plurality ofcolumns. The number of electrodes of array 202 may vary according toneed and may be over 10, over 20, over 30, over 40, or over 50electrodes. The electrodes may perform bipolar stimulation such thatcurrent passes from one electrode to another electrode to stimulate anerve or a group of nerves in between the two electrodes. Electrodes ofarray 202 may have a tissue friendly shape configured to reduce adversetissue reaction that may lead to fibrosis formation around theelectrode. For example, the electrodes may be sized and shaped such thata convex, spherical, or flat shaped portion is exposed on the flexiblesubstrate, avoiding sharp surfaces that may damage or irritate thetissue. The electrodes may be made of platinum, gold, or otherconductible implantable material suitable for electrical stimulation ofnerves.

The flexible substrate(s) having array 202 of electrodes is sized andshaped to abut at least a portion of a pelvic plexus of a patient. Theflexible substrate(s) is configured to bend, e.g., to an arc shape, andmay be implanted (e.g., during prostatectomy surgery) on the pelvicplexus. Preferably, the flexible substrate(s) may be conformed to ananatomical shape of a portion of the pelvic plexus and may cover part orthe entire area of the pelvic plexus so that at least one of theelectrodes of array 202 is in optimal contact with the cavernosal nerve.The flexible substrate(s) may comprise a structural matrix of siliconeor other flexible non-conductible material, which allows adaptation andmolding to the local anatomy required for better positioning and tominimize tissue reaction. The flexible substrate(s) may have a flatstructure designed in a suitable shape (e.g., rectangular, squared,oval, ellipse, trapezoid) and dimensioned to better adapt to eachpatient's anatomy and need.

As illustrated, implantable stimulation unit 200 includes first flexiblesubstrate 204 and second flexible substrate 206 such that implantablestimulation unit 200 resembles a T-shape. Preferably, first flexiblesubstrate 204 is configured to conform to a first half of the pelvicplexus and second flexible substrate 206 is configured to conform to asecond half of the pelvic plexus.

As illustrated, implantable stimulation unit 200 includes a firstportion of array 202 of electrodes disposed on first flexible substrate204 and a second portion of array 202 of electrodes disposed on secondflexible substrate 206. The stimulation circuit may be configured tocause one or more electrodes of the first portion of array 202 ofelectrodes disposed on first flexible substrate 204 and one or moreelectrodes of the second portion of array 202 of electrodes disposed onsecond flexible substrate 206 to supply electrical stimulation at a sametime in a bilateral stimulation manner.

Implantable stimulation unit 200 may include at least one anchor,preferably individually coupled to a flexible substrate, configured tomaintain the flexible substrate in contact with the pelvic plexus. Theanchor may be sutures, biocompatible matrix, or biocompatible glue.Implantable stimulation unit 200 also may be encapsulated in one or morebiocompatible materials suitable for long-term implantation (e.g.,titanium cage, silicone cage). In one embodiment, the flexiblesubstrate(s) include one or more cavities in between the electrodes orat specific regions of the substrate(s) configured to permit connectivetissue growth in and/or through the substrate to enhance anchoring andfixation in the pelvic cavity.

Cable 208 is configured to electrically couple the electrodes of array202 to programmable controller 300. Cable 208 may be an insulatedmulti-conductor cable having an independent wire for each electrode ofarray 202. Cable 208 may include branches, as illustrated, permittingconnection with electrodes on multiple flexible substrates.

Programmable controller 300 includes circuitry configured to storestimulation routines and to cause electrodes of array 202 to supplyelectrical stimulation at parameters defined by the stimulationroutines. Such parameters may include pair(s) of electrodes to be usedfor stimulation, pulse duration, frequency of alternating current,voltage, current, period of stimulation.

Programmable controller 300 may be controlled by, and optionally poweredby, external patient controller 400. External patient controller 400 hasuser interface 402 that permits a user, e.g., patient, physician,caregiver, to adjust a limited number of operational parameters ofprogrammable controller 300 including starting and stopping astimulation session. Programmable controller 300 communicates withexternal patient controller 400 via respective communication units,which may each comprise an inductive coil and/or RF transceiver,configured to communicate information in a bidirectional manner across apatient's skin and, optionally, to transmit power to programmablecontroller 300. For example, external patient controller 400 mayselectively activate programmable controller 300 responsive to userinput received at user interface 402 via respective telemetry (or RF)systems in controllers 300 and 400. In a preferred embodiment, a limitednumber of stimulation parameters may be adjusted at user interface 402to minimize the chance of injury caused by adjustments made bynon-physician users. In an alternative embodiment, external patientcontroller 400 also may send adjustments to stimulation parameters;e.g., pair(s) of electrodes to be used for stimulation, pulse duration,frequency of alternating current, voltage, current, period ofstimulation; to programmable controller 300 responsive to user inputreceived at user interface 402. In one embodiment, external patientcontroller 400 may selectively activate desired subsets of array 202 ofelectrodes to determine the empirically determined subset of array 202of electrodes and to cause nonvolatile memory of programmable controller300 to store the identity of the empirically determined subset of array202 of electrodes and the stimulation routine sufficient to cause sexualarousal. The subset of array 202 of electrodes may include one or moreelectrodes within the array of electrodes. The one or more electrodeswithin array 202 of electrodes may be adjacent to each other or spacedapart.

External patient controller 400 may be specifically designed for usewith implantable stimulation unit 200 or external patient controller 400may be a smartphone, laptop, tablet, smartwatch, or the like programmedto communicate with implantable stimulation unit 200. Accordingly,external patient controller 400 may use an application or “app”downloaded from an app store to interface with implantable stimulationunit 200 and/or external physician controller 500, and may use cellular,802.11 WiFi, Zigbee, and/or BLUETOOTH™ chipset(s) for communication withthose devices.

External physician controller 500 is configured to control programmablecontroller 300 and may communicate directly with programmable controlleror via external patient controller 400. In FIG. 1, external physiciancontroller 500 is a computer having a non-transitory computer readablemedium programmed with instructions that, when run on the computer,cause the computer to provide programming to programmable controller300. External physician controller 500 may be coupled wirelessly toprogrammable controller 300 and/or external patient controller 400 suchthat external physician controller 500 may download for review datastored on programmable controller 300 and/or external patient controller400. External physician controller 500 also may transfer programmingdata to programmable controller 300 to reprogram stimulation parametersprogrammed into programmable controller 300. For example, externalphysician controller 500 may be used to program and adjust parameterssuch as pair(s) of electrodes to be used for stimulation, pulseduration, frequency of alternating current, voltage, current, and periodof stimulation. External physician controller 500 also may be configuredto upload and store data retrieved from programmable controller 300 to aremote server for later access by the physician. In one embodiment,external physician controller 500 may selectively activate desiredsubsets of array 202 of electrodes to determine the empiricallydetermined subset of array 202 of electrodes and to cause nonvolatilememory of programmable controller 300 to store the identity of theempirically determined subset of array 202 of electrodes and thestimulation routine sufficient to cause sexual arousal.

External physician controller 500 may be configured to selectivelyactivate desired subsets of array 202 of electrodes by causingmicroprocessor of programmable controller 300 to execute a scanningprotocol stored in nonvolatile memory of programmable controller 300 todetermine the empirically determined subset of array 202 of electrodesand to cause nonvolatile memory of programmable controller 300 to storethe identity of the empirically determined subset of array 202 ofelectrodes and the stimulation routine sufficient to cause sexualarousal. The scanning protocol may be configured to cause microprocessorof programmable controller 300 to supply electrical stimulation via thestimulation circuit by activating varying subsets of the array ofelectrodes in a predetermined manner at stimulation parameters todetermine the empirically determined subset of array 202 of electrodesand optimal stimulation parameters. The stimulation parameters may bethe same for each subset, varied from subset to subset, the same forselect subsets and varied for other subsets, and/or varied at one ormore subsets throughout the protocol. Activating varying subsets of thearray of electrodes in a predetermined manner may include a first timeand a second time, such that a first subset of array 202 of electrodesis activated at the first time and a second subset of array 202 ofelectrodes is activated at the second time in an interpulse manner.Activating in an interpulse manner may include, for example, activatingthe first subset of array 202 of electrodes while no other subset ofarray 202 of electrodes is activated at such activation time.Subsequently, when the first subset of array 202 of electrodes is nolonger activated, the second subset of array 202 of electrodes isactivated while no other subset of array 202 of electrodes is activated,as will be readily apparent to one skilled in the art. One or moreadditional subsets may be activated while other subset(s) remaininactive.

In one embodiment, external physician controller 500 is used in apost-operative (e.g., prostatectomy) period to determine the empiricallydetermined subset of array 202 of electrodes yielding the best erectileresponse. The stimulation parameters are stored within memory ofprogrammable controller 300 such that erection may be achieved usingthose parameters at a later time, e.g., responsive to user input atexternal patient controller 400.

External physician controller 500 may be specifically designed for usewith implantable stimulation unit 200 or external physician controller400 may be a smartphone, laptop, tablet, desktop computer, or the likeprogrammed to communicate with implantable stimulation unit 200.Accordingly, external physician controller 500 may use software such asan application or “app” downloaded from an app store to interface withimplantable stimulation unit 200 and/or external patient controller 400,and may use cellular, 802.11 WiFi, Zigbee, and/or BLUETOOTH™ chipset(s)for communication with those devices. External physician controller 500may communicate directly with implantable stimulation unit 200 or withimplantable stimulation unit 200 via external patient controller 400.

Referring now to FIGS. 2A and 2B, exemplary electrode shapes for use inimplantable stimulation unit 200 are described. Electrodes 210, 212, 214each have a tissue friendly shape configured to reduce adverse tissuereaction that may lead to fibrosis formation around the electrode.Electrode 210 has a convex portion extending from flexible substrateportion 216 and is independently coupled to the circuitry ofprogrammable controller 300 by wire 218 of the cable. Electrode 212 hasa spherical portion extending from flexible substrate portion 216 and isindependently coupled to the circuitry of programmable controller 300 bywire 220 of the cable. Electrode 214 is flat and is flush with thesurface of flexible substrate portion 216 and is independently coupledto the circuitry of programmable controller 300 by wire 222 of thecable. Advantageously, each of the electrode shapes does not have asharp surface that may damage or irritate the tissue. As will also beunderstood by one of skill in the art, array 202 of electrodes may useone, two, or three of these electrodes shapes or other suitable tissuefriendly shape(s) in array 202 of electrodes.

Referring now to FIGS. 2C, 2D, and 2E, exemplary implantable stimulationsystem 200 is shown. FIGS. 2D and 2E illustrate that first and secondflexible substrates 204 and 206 are configured to bend, e.g., to an arcshape, and may be implanted (e.g., during prostatectomy surgery) on thepelvic plexus. Preferably, first and second flexible substrates 204 and206 are conformable to an anatomical shape of a portion of the pelvicplexus. Because the pelvic plexus has a pair of nerve groups, first andsecond flexible substrates 204 and 206 may each cover part or the entirearea of one nerve group of the pair so that at least one of theelectrodes of array 202 is in optimal contact with the cavernosal nerve.For example, first flexible substrate 204 may have a length betweenabout 1 cm to about 5 cm, about 1 cm to about 4 cm, about 1 cm to about3 cm, about 1 cm to about 2 cm, or about 2 cm to about 4 cm. Inaddition, first flexible substrate 204 may have a width about 1 cm toabout 3 cm, about 1 cm to about 2 cm, or about 1.5 cm to about 2.5 cm.First flexible substrate 204 may have a thickness about 0.3 mm to about3 mm, about 0.5 mm to about 2.5 mm, about 0.5 mm to about 2 mm, about0.5 mm to about 1.5 mm, or about 0.5 mm to about 1.0 mm. As anotherexample, second flexible substrate 206 may have a length between about 1cm to about 5 cm, about 1 cm to about 4 cm, about 1 cm to about 3 cm,about 1 cm to about 2 cm, or about 2 cm to about 4 cm. In addition,second flexible substrate 206 may have a width about 1 cm to about 3 cm,about 1 cm to about 2 cm, or about 1.5 cm to about 2.5 cm. Secondflexible substrate 206 may have a thickness about 0.3 mm to about 3 mm,about 0.5 mm to about 2.5 mm, about 0.5 mm to about 2 mm, about 0.5 mmto about 1.5 mm, or about 0.5 mm to about 1.0 mm. First and secondflexible substrates 204 and 206 may have the same dimensions ordifferent dimensions. In addition, the distance between first flexiblesubstrate 204 and second flexible substrate 206, when implanted, may beabout 0.5 cm to about 8 cm, about 1 cm to about 7 cm, about 2 cm toabout 6 cm, or about 3 cm to about 5 cm. Cable 208 is also flexible topermit a physician to manipulate programmable controller 300 to implantprogrammable controller 300 at a suitable location, e.g., between theskin and the pelvic bone.

With respect to FIG. 3, a generalized schematic diagram of the internalfunctional components of programmable controller 300 is now described.Programmable controller 300 is configured to cause the electrodes tostimulate in accordance with programming data stored in the memory ofprogrammable controller 300. Programmable controller 300 may includemicroprocessor 302, nonvolatile memory 304, communication unit 306,system sensors 308, power supply 310, stimulation circuit 312, anddemultiplexer 314.

Microprocessor 302 is electrically coupled to, and configured tocontrol, the internal functional components of programmable controller300. Microprocessor 302 may comprise a commercially availablemicrocontroller unit including a programmable microprocessor, volatilememory, nonvolatile memory 304 such as EEPROM for storing programmingand nonvolatile storage, e.g., Flash memory, for storing firmware and alog of system operational parameters and patient data. The memory ofmicroprocessor 302 stores program instructions that, when executed bymicroprocessor 302, cause the processor and the functional components ofprogrammable controller 300 to provide the functionality ascribed tothem herein. Microprocessor 302 is configured to be programmable suchthat programming data (e.g., stimulation parameters, identity of anempirically determined subset of the array of electrodes, stimulationroutines) is stored in nonvolatile memory 304 of microprocessor 302 andmay be adjusted using external patient controller 400 and/or externalphysician controller 500.

Microprocessor 302 may be programmable to allow electrical stimulationbetween any chosen combination of electrodes on the array, thusproviding a simple bipolar configuration. Microprocessor 302 further maybe programmed with a routine to selectively activate desired subsets ofthe array of electrodes to determine an empirically determined subset ofthe array of electrodes and cause nonvolatile memory 304 to store astimulation routine used by microprocessor 302. For example,microprocessor 302 may direct power supply 310 to send an electricalsignal via stimulation circuit 312 to one or more electrodes, usingdemultiplexer 314, which emit electrical power. In one embodiment, thestimulation routine is used by microprocessor 302 to supply electricalstimulation via stimulation circuit 312 and the pelvic plexus to atleast one cavernous nerve sufficient to cause sexual arousal, e.g., anerection. The routine may selectively activate the desired subsetsautomatically and/or responsive to user input at external patientcontroller 400 and/or external physician controller 500. The desiredsubset of the array (e.g., one or more stimulation electrodes) yieldsthe best sexual arousal, e.g., erectile response, and is stored inmemory. The desired subset may be determined in a direct fashion (e.g.,stimulate each electrode sequentially and observe the evoked erectileresponse) or in an indirect/peripheral fashion (e.g., stimulate thecavernosal nerve distally, for example via external electrodes disposedon the skin of the penis, and record the signal received by theelectrodes upstream). The identity of the electrode receiving the bestsignal is stored for later stimulation and the received electrodesignals and/or the identity of the electrode receiving the best signalmay be transmitted to external patient controller 400 and/or externalphysician controller 500.

The stimulation parameters are selected to provide sexual arousal, topromote nerve regeneration, and/or to improve nerve regeneration totreat sexual disorders such as erectile dysfunction and female sexualarousal disorder. For example, stimulation may cause and maintain anerection and may promote and/or improve nerve (e.g., nerve(s) of thepelvic plexus and/or cavernous nerve(s)) regeneration over time. As anexample, pulse duration may be programmed to be between about 0.5 msecto about 10 msec, about 0.5 msec to about 5 msec, about 1 msec to about4 sec, or about 1 msec to about 3 msec. Frequency of alternating currentmay be programmed to be between about 10 Hz to about 30 Hz, about 10 Hzto about 25 Hz, about 10 Hz to about 20 Hz, or about 15 Hz to about 25Hz. Voltage may be programmed to be between about 1 V to about 15 V,about 5 V to about 10V, about 1 V to about 5 V, or about 10 V to about15V. Current may be programmed to be between about 1 milliamp to about100 milliamps, about 1 milliamp to about 50 milliamps, about 1 milliampto about 20 milliamps, about 20 milliamps to about 50 milliamps, about50 milliamps to about 100 milliamps, or about 75 milliamps to about 100milliamps. Period of stimulation may be programmed to automaticallystimulate during predetermined times or may stimulate responsive to userinput, e.g., at user interface 402. For example, stimulation may bemaintained during a portion or during the entire period of desirederection. For nerve regeneration, it may be preferable to stimulate atpredetermined intervals over time. For example, automatic stimulationmay occur hourly, once a day, twice a day, three times a day, four timesa day, every other day, every three days, or weekly for a period of 10min to 2 hours, 10 min to 1 hour, 10 min to 30 min, 10 min to 20 min, or1 hour to 2 hours. Preferably, stimulation for nerve regeneration occursusing oscillating current or low-frequency electrical stimulation.

Microprocessor 302 is coupled to communication unit 306 having circuitryconfigured to communicate external patient controller 400 and/orexternal physician controller 500. Communication unit 306 permitstransmission of stimulation commands, and optionally power, betweenprogrammable controller 300 and external patient controller 400 suchthat programmable controller 300 may be powered, programmed, and/orcontrolled by external patient controller 400. For example,microprocessor 302 may start or stop a stimulation session or to conductan assessment to determine optimal subset of the array of electrodesresponsive to stimulation commands received from a correspondingcommunication unit (e.g., an inductive unit having a telemetry systemand coil and/or a RF unit having a transceiver and antenna) of externalpatient controller 400. Communication unit 306 further permitstransmission of programming data, and optionally power, betweenprogrammable controller 300 and external physician controller 500 suchthat programmable controller 300 may be powered, programmed, and/orcontrolled by external physician controller 500. For example,microprocessor 302 may direct changes to pair(s) of electrodes to beused for stimulation, pulse duration, frequency of alternating current,voltage, current, and/or period of stimulation and may conduct anassessment to determine optimal subset of the array of electrodesresponsive to programming data received from a correspondingcommunication unit (e.g., an inductive unit having a telemetry systemand coil and/or a RF unit having a transceiver and antenna) of externalphysician controller 500.

Communication unit 306 may include a telemetry system electricallycoupled to an inductive coil. The technology for telemetry systems andcoils is well known to one skilled in the art and may include a magnet,a short range telemetry system, a longer range telemetry system (such asusing MICS RF Telemetry available from Zarlink Semiconductor of Ottawa,Canada), or technology similar to a pacemaker programmer. Alternatively,the coil may be used to transmit power only, and separate radiofrequency transmitters may be provided in programmable controller 300,external patient controller 400, and/or external physician controller500 for establishing bidirectional or unidirectional data communication.

Communication unit 306 also may include (with or without the telemetrysystem and coil) a communications circuit employing a transceivercoupled to an antenna (which may be inside or external to the hermetichousing). The transceiver preferably comprises a radio frequency (RF)transceiver and is configured for bi-directional communications via theantenna with a similar transceiver circuit disposed in external patientcontroller 400 and/or external physician controller 500. For example,the transceiver may receive stimulation commands from external patientcontroller 400 and programming data from external physician controller500. Microprocessor 302 may direct changes to pair(s) of electrodes tobe used for stimulation, pulse duration, frequency of alternatingcurrent, voltage, current, and/or period of stimulation, may start orstop a stimulation session, and/or may conduct an assessment todetermine optimal subset of the array of electrodes, responsive toprogramming data and/or stimulation commands received from acorresponding transceiver and antenna of external patient controller 400and/or external physician controller 500 via the antenna and thetransceiver of communication unit 306. The transceiver also may includea low power mode of operation, such that it periodically awakens tolisten for incoming messages and responds only to those messagesincluding the unique device identifier assigned to that programmablecontroller. In addition, the transceiver may employ an encryptionroutine to ensure that messages sent from, or received by, programmablecontroller 300 cannot be intercepted or forged. Communication unit 306may include a wireless chipset; e.g., WiFi, BLUETOOTH™, cellular,Zigbee, or the like; thereby enabling programmable controller 300 tocommunicate wirelessly with external patient controller 400 and/orexternal physician controller 500.

System sensors 308 may comprise one or more sensors that monitoroperation of the systems of programmable controller 300, and log datarelating to system operation as well as system faults, which may bestored in a log for later readout using external physician controller500. Microprocessor 302 may be configured to receive a sensor signalfrom system sensors 308 and to adjust the stimulation parameters basedon the sensor signal. Sensors 308 may include, for example, a humiditysensor to measure moisture within the housing of programmable controller300, which may provide information relating to the state of theelectronic components, and/or a temperature sensor, e.g., for measuringbattery temperature during charging to ensure safe operation of thebattery. Data from the system sensors may be logged by microprocessor302 and stored in nonvolatile memory 304 for later transmission toexternal physician controller 500.

Power supply 310 powers the electrical components of programmablecontroller 300, and may comprise a primary cell or battery, a secondary(rechargeable) cell or battery or a combination of both. Alternatively,power supply 310 may not include a cell or battery, but instead comprisea capacitor that stores energy transmitted through the skin via aTranscutaneous Energy Transmission System (TETs), e.g., by inductivecoupling. In a preferred embodiment, power supply 310 comprises alithium ion battery.

Stimulation circuit 312 is configured to send pulses, using energysupplied from power supply 310, to the electrodes of the array such thatthe selected electrode(s) supply electrical stimulation at the desiredparameters.

Microprocessor 302 further may be coupled to demultiplexer 314 so thatany subset of electrodes of the electrode array may be selectablycoupled to stimulation circuit 312. In this way, an appropriateelectrode set may be chosen from the entire selection of electrodesimplanted in the patient's body to achieve a desired therapeutic effect.Demultiplexer 314 preferably operates at high speed, thereby allowingsuccessive stimulation pulses to be applied to different electrodecombinations.

With respect to FIG. 4, a generalized schematic diagram of the internalfunctional components of external patient controller 400 is nowdescribed. External patient controller 400 may include user interface402, programmable microprocessor 404, communication unit 406, powersupply 408, and input and output circuitry (I/O) 410. As explainedabove, external physician controller 400 may be specifically designedfor use with implantable stimulation unit 200 or may be a multipurposesmartphone, laptop, tablet, smartwatch, or the like programmed tocommunicate with implantable stimulation unit 200 and/or externalpatient controller 500. In the latter case, user interface 402,programmable microprocessor 404, communication unit 406, power supply408, and I/O 410 may be hardware previously installed on the smartphone,laptop, tablet, smartwatch, or the like.

Microprocessor 404 is electrically coupled to, and configured tocontrol, the internal functional components of external patientcontroller 400. Microprocessor 404 may comprise a commercially availablemicrocontroller unit including a programmable microprocessor, volatilememory, nonvolatile memory such as EEPROM for storing programming andnonvolatile storage, e.g., Flash memory, for storing firmware and a logof system operational parameters and patient data. The memory ofmicroprocessor 404 may store program instructions that, when executed bythe processor of microprocessor 404, cause the processor and thefunctional components of external patient controller 400 to provide thefunctionality ascribed to them herein. Microprocessor 404 is configuredto be programmable. For example, microprocessor 404 may store and adjuststimulation parameters; e.g., pair(s) of electrodes to be used forstimulation, pulse duration, frequency of alternating current, voltage,current, and/or period of stimulation; responsive to user input receivedat user interface 402 and/or at an external physician controller 500 andsend stimulation commands and programming data to programmablecontroller 300 via communication unit 406.

Microprocessor 404 may be coupled to communication unit 406, which isconfigured to communicate with programmable controller 300 and externalphysician controller 500. Communication unit 406 may include aninductive unit having a telemetry system and coil and/or a RF unithaving a transceiver and antenna with a wireless chipset; e.g., WiFi,BLUETOOTH™, cellular, Zigbee, or the like; thereby enabling externalpatient controller 400 to communicate wirelessly with programmablecontroller 300 and/or external physician controller 500 and tooptionally supply power to programmable controller 300.

User interface 402 is configured to receive user input and to displayinformation to the user. User interface 402 may include buttons, LEDs, adisplay, a touch screen, a keypad, a microphone, a speaker, a trackball,or the like for receiving user input and/or displaying information tothe user. For example, user interface 402 may display currentstimulation parameters and permit a user to adjust the stimulationparameters. In a preferred embodiment, a limited number of stimulationparameters may be adjusted at user interface 402 to minimize the chanceof injury caused by adjustments made by non-physician users. Forexample, user interface 402 may only permit a user to start or stop astimulation session using the empirically determined subset of array 202of electrodes and the stimulation routine sufficient to cause sexualarousal.

Power supply 408 powers the electrical components of external patientcontroller 400, and may comprise a primary cell or battery, a secondary(rechargeable) cell or battery or a combination of both. Alternatively,power supply 408 may be a port to allow external patient controller 400to be plugged into a conventional wall socket for powering components.

Input and output circuitry (I/O) 410 may include ports for datacommunication such as wired communication with a computer and/or portsfor receiving removable memory, e.g., SD card, upon which programinstructions or data related to external patient controller 400 use maybe stored.

Referring now to FIG. 5, the software implemented on external physiciancontroller 500 is now described. The software comprises a number offunctional blocks, schematically depicted in FIG. 5, including mainblock 502, event logging block 504, data download block 506,configuration setup block 508, user interface block 510, alarm detectionblock 512, sensor calibration block 514, firmware upgrade block 516,device identifier block 518, and status information block 520. Thesoftware preferably is written in C++ and employs an object orientedformat. In one preferred embodiment, the software is configured to runon top of a Microsoft Windows® (a registered trademark of MicrosoftCorporation, Redmond, Wash.) or Unix-based operating system, such as areconventionally employed on desktop and laptop computers. As discussedabove, the computer may include a transceiver, an antenna, and awireless card; e.g., conforming to the IEEE 802.11 standard, cellular,BLUETOOTH™, Zigbee, or the like; thereby enabling programmablecontroller 300 and/or external patient controller 400 to communicatewirelessly with external physician controller 500.

Main block 502 preferably includes a main software routine that executeson the physician's computer, and controls overall operation of the otherfunctional blocks. Main block 502 enables the physician to downloadevent data and alarm information stored on programmable controller 300and/or external patient controller 400, to his office computer, and alsopermits external physician controller 500 to directly control operationof programmable controller 300. Main block 502 also enables thephysician to upload firmware updates and configuration data toprogrammable controller 300.

Event Log block 504 is a record of operational data downloaded fromprogrammable controller 300 and may include, for example, treatmentsession start and stop times, current stimulation parameters,stimulation parameters from previous treatment sessions, sensor data,battery current, battery voltage, battery status, and the like. Theevent log also may include the occurrence of events, such as alarms orother abnormal conditions.

Data Download block 506 is a routine that commands programmablecontroller 300, to transfer data to external physician controller 500for download after programmable controller 300 is coupled to externalphysician controller 500. Data Download block 506 may initiate, eitherautomatically or at the instigation of the physician via user interfaceblock 510, downloading of data stored in the event log.

Configuration Setup block 508 is a routine that configures theparameters stored within programmable controller 300 that controloperation of programmable controller 300. The interval timing parametersmay determine, e.g., how long the processor remains in sleep mode priorto being awakened to listen for radio communications or to controlprogrammable controller 300 operation. The interval timing parametersmay control, for example, the duration of a stimulation session.Interval timing settings transmitted to programmable controller 300 alsomay determine when and how often event data is written to the memory inmicroprocessor 302. In an embodiment in which external physiciancontroller 500 is also configured to transfer data to external patientcontroller 400, external physician controller 500 also may be used toconfigure timing parameters used by the firmware executed bymicroprocessor 404 of external patient controller 400. Block 508 alsomay be used by the physician to configure parameters stored within thememory of microprocessor 302 relating to limit values on operation ofmicroprocessor 302. These values may include times when programmablecontroller 300 may and may not operate, etc.

Block 508 also may configure parameters stored within the memory ofmicroprocessor 302 relating to control of operation of programmablecontroller 300. These values may include stimulation parameters.

User interface block 510 handles display of information retrieved fromprogrammable controller 300 and/or external patient controller 400 anddata download block 506, and presents that information in an intuitive,easily understood format for physician review. Such information mayinclude status of programmable controller 300, treatment session startand stop times, current stimulation parameters, stimulation parametersfrom previous treatment sessions, sensor data, battery status, and thelike. User interface block 510 also generates user interface screensthat permit the physician to input information to configure the sessiontiming, stimulation parameters, requests to determine the subset of thearray of electrodes optimal for sexual arousal, etc.

Alarm detection block 512 may include a routine for evaluating the dataretrieved from programmable controller 300 and flagging abnormalconditions for the physician's attention. For example, alarm detectionblock 512 may flag when a parameter measured by system sensors 308 isabove or below a predetermined threshold.

Sensor calibration block 514 may include a routines for testing ormeasuring drift, of system sensors 308 employed in programmablecontroller 300, e.g., due to aging or change in humidity. Block 514 maythen compute offset values for correcting measured data from thesensors, and transmit that information to programmable controller 300for storage in the nonvolatile memory of microprocessor 302.

Firmware upgrade block 516 may comprise a routine for checking theversion numbers of the controller firmware installed on programmablecontroller 300 and/or external patient controller 400 and identifywhether upgraded firmware exists. If so, the routine may notify thephysician and permit the physician to download revised firmware toprogrammable controller 300 and/or external patient controller 400, innonvolatile memory.

Device identifier block 518 may include a unique identifier forprogrammable controller 300 that is stored in the nonvolatile memory ofmicroprocessor 302 and a routine for reading that data when externalphysician controller 500 is coupled to programmable controller 300. Thedevice identifier also may be used by programmable controller 300 toconfirm that wireless communications received from external patientcontroller 400 and/or external physician controller 500 are intended forthat specific programmable controller. Likewise, this information isemployed by external patient controller 400 and/or external physiciancontroller 500 to determine whether a received message was generated bythe programmable controller associated with that system. Finally, thedevice identifier information may be employed by external physiciancontroller 500 to confirm that external patient controller 400 andprogrammable controller 300 constitute a matched set.

Status information block 520 comprises a routine for interrogatingprogrammable controller 300 to retrieve current status data fromprogrammable controller 300. Such information may include, for example,battery status, stimulation parameters, the date and time on theinternal clocks of treatment sessions, version control information forthe firmware and hardware currently in use, and sensor data.

Referring now to FIGS. 6 and 7, an exemplary method for implanting animplantable stimulation unit is described. FIG. 6 is a schematicrepresentation of the local anatomy showing the bladder B, prostate P, apair of nerve groups known as the pelvic plexus PP, the testis T, andthe penis PS. In this example, implantable stimulation unit 200 isimplanted following prostatectomy, although the disclosure is notlimited thereto. Preferably, implantable stimulation unit 200 isinserted in the patient via the incision used to remove the prostate P.Implantable stimulation unit 200 may be implanted using a robotic-guidedsurgery system. Insertion may be visualized using, for example,fluoroscopy, acoustic, anatomic, or CT guidance. The incision may be inthe lower abdomen or perineum. In one embodiment, one or more trocarsare inserted in the incision and implantable stimulation unit 200;including first flexible substrate 204, second flexible substrate 206,cable 208, and programmable controller 300; is sized and shaped to beimplanted through the respective lumen(s) of the one or more trocars. Asis shown in FIG. 7, the first and second flexible substrates areconfigured to bend, e.g., to an arc shape, and implanted on the pelvicplexus PP permitting molding, apposition, and adaptation to the localanatomy by the substrates. Preferably, the first and second flexiblesubstrates are conformable to an anatomical shape of a portion of thepelvic plexus PP. Because the pelvic plexus PP has a pair of nervegroups, the first and second flexible substrates may each cover part orthe entire area of one nerve group of the pair so that at least one ofthe electrodes of the array is in optimal contact with the cavernosalnerve. The first and second flexible substrates may be anchored totissue, e.g., via one or more sutures and/or biocompatible glue. Thecable of implantable stimulation unit 200 is also flexible to permit aphysician to manipulate the programmable controller such that theprogrammable controller is implanted at a suitable location, e.g.,subderma and/or subderma between the skin and the pelvic bone. Theprogrammable controller may be anchored to tissue, e.g., via one or moresutures and/or biocompatible glue. The incisions may then be closed.Advantageously, the implantation procedure is fast, thereby avoidinglong periods of surgery. In addition, optimal placement of theelectrodes relative to the cavernosal nerve does not need to bedetermined during surgery and may be determined post-surgery. Electricalstimulation system 100 provides a painless, safe, easier, non-traumatic,and more effective alternative for the treatment of sexual disorderssuch as ED.

In FIG. 8, an exemplary method for empirically determining a subset ofthe array of electrodes positioned to supply electrical stimulation toat least one cavernous nerve via the pelvic plexus to cause sexualarousal, e.g., an erection, preferably post-implantation, is shown. Inmethod 800, at 802, stimulation parameters are set which may include thepair(s) of electrode in the array to be used, pulse duration, frequencyof alternating current, voltage, current, and period of stimulation.Stimulation parameters may be set at external patient controller 400,but are preferably set at external physician controller 500. At 804,electrical stimulation is supplied to tissue, e.g., pelvic plexus,between the selected electrode pair(s) of the array at the setstimulation parameters. The selected electrode pair(s) of the array atthe set stimulation parameters may be selected by a physician via theexternal physician controller and/or determined as a result of thescanning protocol described above. At 806, it is observed whether sexualarousal, e.g., an erection, is achieved. If not, stimulation parametersmay be reset for the selected electrode pair(s) or different electrodepair(s) may be selected for stimulation with the same parameters or atadjusted parameters. If sexual arousal is achieved, the stimulationparameters, including the electrode pair(s), are stored in memory atprogrammable controller 300, external patient controller 400, and/orphysician controller 500. Optionally, even after sexual arousal isachieved, further stimulation may be conducted at the electrode pair(s)using adjusted stimulation parameters or further different electrodepair(s) may be selected for stimulation with the same parameters or atadjusted parameters, at 810, to determine if greater sexual arousal canbe achieved, at 812. If not, stimulation, at 810, may be repeated withdifferent configurations or the testing may end and the parametersstored at 808 may be used. If greater sexual arousal is achieved, thestimulation parameters, including the electrode pair(s), are stored inmemory at programmable controller 300, external patient controller 400,and/or physician controller 500 as the optimal parameters and thepreviously stored parameters at 808 may be overwritten. Optionally, evenafter greater sexual arousal is achieved, further stimulation may beconducted at the electrode pair(s) using adjusted stimulation parametersor further different electrode pair(s) may be selected for stimulationwith the same parameters or at adjusted parameters, at 810, to determineif even greater sexual arousal can be achieved, at 812. Once the user issatisfied that the optimal parameters have been determined, eitherbecause all electrode pairings in the array were tested or becausesuitable sexual arousal was achieved, the optimal parameters are stored.In this manner, a stimulation routine at the optimal parameters may beinitiated by patient external controller 400 and/or external physiciancontroller 500 at a later time; e.g., minutes, hours, days, months,years later; to cause sexual arousal, e.g., an erection.

While various illustrative embodiments of the invention are describedabove, it will be apparent to one skilled in the art that variouschanges and modifications may be made therein without departing from theinvention. The appended claims are intended to cover all such changesand modifications that fall within the true scope of the invention.

What is claimed is:
 1. A method of treating a sexual disorder, themethod comprising: placing an array of electrodes adjacent a prostate orwhere a native prostate was located prior to prostatectomy; andsupplying electrical stimulation via at least one electrode of the arrayof electrodes to stimulate a pelvic plexus and thereby at least onecavernous nerve to cause an erection.
 2. The method of claim 1, whereinthe array of electrodes is disposed on at least one flat flexiblesubstrate sized and shaped to abut at least a portion of the pelvicplexus and configured to bend to conform to an anatomical shape of theportion of the pelvic plexus.
 3. The method of claim 2, whereinelectrodes of the array of electrodes comprise a plurality of rows and aplurality of columns disposed on the at least one flat flexiblesubstrate and each electrode is individually selectable.
 4. The methodof claim 2, wherein the at one least flat flexible substrate comprises afirst flat flexible substrate configured to conform to a first half ofthe pelvic plexus and a second flat flexible substrate configured toconform to a second half of the pelvic plexus.
 5. The method of claim 4,wherein a first portion of the array of electrodes is disposed on thefirst flat flexible substrate and a second portion of the array ofelectrodes is disposed on the second flat flexible substrate, whereinsupplying the electrical stimulation via the at least one electrode ofthe array of electrodes comprises supplying the electrical stimulationto one or more electrodes of the first portion and one or moreelectrodes of the second portion at a same time in a bilateralstimulation manner.
 6. The method of claim 1, wherein supplying theelectrical stimulation via the at least one electrode of the array ofelectrodes comprises initiating a stimulation routine executed by animplantable processor operatively coupled to the array of electrodes. 7.The method of claim 6, wherein the stimulation routine is initiatedresponsive to a command wirelessly transmitted by an external patientcontroller to the implantable processor.
 8. The method of claim 6,wherein the stimulation routine specifies one or more of pulse duration,frequency of alternating current, voltage, current, or period ofstimulation sufficient to cause the erection.
 9. The method of claim 6,further comprising adjusting the stimulation routine by adjustingstimulation parameters at the implantable processor responsive to one ormore commands wirelessly received.
 10. The method of claim 9, furthercomprising wirelessly sending the one or more commands by an externalphysician controller or an external patient controller after supplyingthe electrical stimulation.
 11. The method of claim 1, furthercomprising empirically determining a subset of the array of electrodescomprising the at least one electrode prior to supplying the electricalstimulation.
 12. The method of claim 11, wherein empirically determiningthe subset of the array of electrodes comprises selectively activatingsubsets of the array of electrodes via an external physician controlleroperatively coupled to the array of electrodes.
 13. The method of claim12, wherein selectively activating the subsets of the array ofelectrodes occurs post implantation of the array of electrodes.
 14. Themethod of claim 11, wherein empirically determining the subset of thearray of electrodes comprises executing a scanning protocol via animplantable processor operatively coupled to the array of electrodes.15. The method of claim 14, wherein executing the scanning protocolcomprises activating varying subsets of the array of electrodes in apredetermined manner to determine the empirically determined subset ofthe array of electrodes.
 16. The method of claim 15, wherein activatingthe varying subsets of the array of electrodes in the predeterminedmanner comprises activating a first subset of the array of electrodes ata first time and activating a second subset of the array of electrodesat a second time in an interpulse manner.
 17. The method of claim 15,wherein activating the varying subsets of the array of electrodes in thepredetermined manner comprises activating a first subset of the array ofelectrodes at a first time and activating either the first subset of thearray of electrodes at different stimulation parameters or a secondsubset of the array of electrodes at a same or different stimulationparameters.
 18. The method of claim 1, further comprising anchoring thearray of electrodes to maintain the array of electrodes in contact withthe pelvic plexus.
 19. The method of claim 18, wherein anchoring thearray of electrodes comprises anchoring the array of electrodes withsutures or biocompatible glue.
 20. The method of claim 1, furthercomprising: receiving an electrical signal emitted by one or moreexternal electrodes disposed on a skin of a penis of the patient via atleast one electrode of the array of electrodes; and recording andstoring information indicative of the received electrical signal.